Browsing Institutt for helse og samfunn by Author "Aarsland, Dag"
Now showing items 1-4 of 4
-
Husebø, Bettina; Flo, Elisabeth; Aarsland, Dag; Selbæk, Geir; Testad, Ingelin; Gulla, Christine; Aasmul, Irene; Ballard, Clive (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2015)Background Nursing home patients have complex mental and physical health problems, disabilities and social needs, combined with widespread prescription of psychotropic drugs. Preservation of their quality of life is an ...
-
Witoelar, Aree; Rongve, Arvid; Almdahl, Ina Selseth; Ulstein, Ingun; Engvig, Andreas; White, Linda Rosemary; Selbæk, Geir; Stordal, Eystein; Andersen, Fredrik; Brækhus, Anne; Saltvedt, Ingvild; Engedal, Knut; Hughes, Timothy; Bergh, Sverre; Bråthen, Geir; Bogdanovic, Nenad; Bettella, Francesco; Wang, Yunpeng; Athanasiu, Lavinia; Bahrami, Shahram; Le Hellard, Stephanie; Giddaluru, Sudheer; Dale, Anders M; Sando, Sigrid Botne; Steinberg, Stacy; Stefansson, Hreinn; Snaedal, Jon; Desikan, Rahul S; Stefansson, Kari; Aarsland, Dag; Djurovic, Srdjan; Fladby, Tormod; Andreassen, Ole Andreas (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)A large fraction of genetic risk factors for Alzheimer’s Disease (AD) is still not identified, limiting the understanding of AD pathology and study of therapeutic targets. We conducted a genome-wide association study (GWAS) ...
-
Sandvik, Reidun Karin Norheim Myhre; Selbæk, Geir; Bergh, Sverre; Aarsland, Dag; Husebø, Bettina (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2016)Objectives To investigate whether it is possible to determine signs of imminent dying and change in pain and symptom intensity during pharmacological treatment in nursing home patients, from day perceived as dying and ...
-
Erdal, Ane; Flo, Elisabeth; Aarsland, Dag; Selbæk, Geir; Ballard, Clive; Slettebø, Dagrun Daltveit; Husebø, Bettina (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)Purpose: Buprenorphine transdermal system is increasingly prescribed in people with advanced dementia, but no clinical trial has investigated the safety and factors associated with discontinuation due to adverse events in ...